GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On October 31, 2024, we reported on a study abstract presented at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting that examined the impact of glucagon-like peptide 1 receptor agonist (GLP-1 RA) use on early-onset colorectal cancer risk in patients with type 2 diabetes (T2D) with and without obesity.

The study

Researchers analyzed data from TriNetX, a large federated deidentified health research network, to identify adults aged less than 50 years with diagnosed T2D subsequently prescribed antidiabetic medications who had not received a prior diagnosis of CRC. Additionally, patients were stratified into 2 groups on the basis of first-time GLP-1 RA use. Researchers also performed a subanalysis based on GLP-1RA use and the presence of obesity. The primary outcome was first diagnosis of EO-CRC after GLP-1RA use.

A total of 2 025 034 drug-naïve patients with T2D were identified for the study; of these, 284 685 were in the GLP-1RA group and 1 740 349 were in the non-GLP-1RA arm. Following propensity score matching, there were 86 186 participants in each group.

The findings

Adults in the GLP-1RA group had significantly lower odds of developing EO-CRC compared to the non-GLP-1RA group (0.6% vs 0.9%; P < .001; odds ratio [OR] 0.61, 95% CI 0.54-0.68), according to the results.

In the subanalysis, investigators observed that participants with obesity and receiving GLP-1RAs had significantly lower odds of developing EO-CRC than those with obesity in the non-GLP-1RA group (0.7% vs 1.1%; P < .001; OR 0.58, 95% CI 0.50-0.67).

Authors' comment

"This is the first large study to demonstrate that GLP-1RAs decrease the risk of developing EO-CRC in patients with T2DM regardless of weight. Future randomized controlled studies are needed to validate these findings, which may have significant implications for CRC prevention in younger patients."

Click here for more details.